Mirum Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $5.6B
- as of Sep 30, 2026
- Shares Outstanding
- 64.9M
- Free Float
- 91.2%
Income Statement
- Revenue
- $521.3M
- Operating Income
- -$22.1M
- Net Income
- -$23.4M
- EBITDA
- $2.1M
- Revenue Growth, 3Y
- 89.1%
- FCF Margin, 3Y Avg
- -8.3%
- FCF Margin, Worst Year
- -38.1%
Cash Flow
- Free Cash Flow
- $54.9M
- FCF Yield
- 1.0%
- Owner FCF Yield
- -0.3%
Balance Sheet
- Cash & Equivalents
- $296.7M
Returns & Capital
- SBC, 3Y Avg
- $51.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $521.3M | $54.9M | 10.5% |
| FY2024 | $336.9M | $9.3M | 2.8% |
| FY2023 | $186.4M | -$71.1M | -38.1% |
| FY2022 | $77.1M | -$120.4M | -156.3% |
| FY2021 | $19.1M | -$132.8M | -693.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges